AXSM Company Profile and Key Details

Q: Who are the executives of AXSM?

Mr. Nick Pizzie CPA, M.B.A.Chief Financial OfficerMr. Hunter Murdock Esq.Gen. Counsel & Sec.Mr. Kevin Laliberte Pharm.D.Executive Vice President of Product StrategyMs. Lori Englebert M.B.A.Executive Vice President of Commercial & Bus. Devel.Mr. Mark L. JacobsonChief Operating Officer & Sec.Dr. Amanda Jones Pharm.D.Senior Vice President of Clinical Devel.Dr. Herriot Tabuteau M.D.Founder, Chairman, Chief Executive Officer & PresJoseph Debrah-Afful CPA, M.B.A.Director of Fin.

NASDAQ : AXSM

Axsome Therapeutics

$188.11

3.61+1.96%

Open: 3:51 PM

58.16

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Axsome Therapeutics, Inc. (AXSM) stock surged +1.96%, trading at $188.11 on NASDAQ, up from the previous close of $184.50. The stock opened at $183.98, fluctuating between $183.69 and $188.29 in the recent session.

Stock Snapshot

184.5

Prev. Close

9.48B

Market Cap

183.69

Day Low

-40.28

P/E Ratio

-4.67

EPS (TTM)

-3.08

Cash Flow per Share

183.98

Open

50.41M

Number of Shares

188.29

Day High

84.14%

Free Float in %

4.04

Book Value

956.61K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	178.00	185.98	175.00	184.50	1.2M
Jan 16, 2026	175.71	178.56	172.05	177.27	604.47K
Jan 15, 2026	177.01	177.01	173.32	174.14	650.55K
Jan 14, 2026	173.66	179.00	172.73	177.01	457.23K
Jan 13, 2026	177.91	177.95	173.67	174.33	587.79K
Jan 12, 2026	172.50	179.45	170.06	176.82	1.17M
Jan 09, 2026	169.10	173.78	168.51	169.38	792.51K
Jan 08, 2026	168.97	170.59	165.75	167.55	748.62K
Jan 07, 2026	171.90	173.73	168.02	170.69	814.95K
Jan 06, 2026	173.00	176.00	170.30	171.88	791.63K
Jan 05, 2026	178.88	179.02	168.58	171.49	1.06M
Jan 02, 2026	183.33	183.33	175.02	178.69	1.43M
Dec 31, 2025	158.49	184.40	158.49	182.64	3.04M
Dec 30, 2025	150.97	153.02	148.14	148.79	509.27K
Dec 29, 2025	152.00	153.15	150.01	150.68	452.87K
Dec 26, 2025	153.76	154.22	151.27	152.05	460.37K
Dec 24, 2025	154.74	155.84	153.50	153.64	145.11K
Dec 23, 2025	155.36	158.56	152.41	154.19	469.86K
Dec 22, 2025	152.65	156.39	152.65	154.70	600.54K
Dec 19, 2025	147.18	154.49	147.18	152.65	974.36K

Contact Details

New York City, NY 10007

United States

https://www.axsome.com 212 332 3241

About Company

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed at $188.11 USD, gaining $3.61 (1.96%) from the previous close of $184.50. The stock is currently trading near its 52-week high $86.99 and $188.37. With a market capitalization of about $9.48 billion, Axsome Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.43). Key stats such as the average daily volume over the past year has been around 635.10 thousand shares, trading with heavier-than-usual volume. Headquartered in New York City, NY, Axsome Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Herriot Tabuteau, the company employs approximately 712 people and listed since November 19, 2015. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

Technical Performance

AXSM has shown sold momentum, gaining 4.34% over the past week and 44.21% over the past quarter, though year-to-date performance is up 1.02%. Short-term trend indicators are bearishly aligned (SMA20 10.38%, SMA50 19.56%, SMA200 50.11%). The stock’s 14-day RSI is 69.19 (firm momentum), while the ATR of 6.76 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 0.06% below its high and over 112.09% above its low. Average 10-day trading volume of 777.75 thousand shares is slightly above the 3-month average of 618.32 thousand, indicating heightened recent market interest.

Valuation Metrics

Axsome Therapeutics, Inc. trades at a P/E ratio of -40.36, slightly below the S&P 500 average, with a price-to-sales ratio of 16.63 and a price-to-book ratio of 125.65 reflecting a rich premium to book value. The P/FCF stands at -92.4, also below market averages. Compared to sector medians, Axsome Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Axsome Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $21.36. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Axsome Therapeutics, Inc. generated EPS of -$4.67 over the past year. Five-year average earnings growth is -24.44%. The latest quarter delivered EPS of -$0.94. The next quarter is forecast at -$0.71. Next year's EPS is expected at $27.26. Analyst sentiment is bullish. Analyst rating data shows there are 24 Strong Buy ratings, 27 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $260.00 to $133.00. The high target offers 40.92% upside. The low target suggests -27.91% downside. The mean target is $183.15. This offers -0.73% upside. Axsome Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 03, 2025, missed forecasts by 15.14%. The prior quarter beat by -8.0%. Over the last six quarters, Apple has recorded several small beats. These include 28.3% in August 05, 2024.

Shareholding & Insider Activity

Axsome Therapeutics, Inc. has 50.41 million shares outstanding. The public float is 42.50 million shares, elevated short interest at 6.69% of float. This equals 2.84 million shares. The short ratio is 5.36 days. Institutional investors hold 90.91% of the float. Insiders own 15.7%. JEFFS ROGER holds 57.51 thousand shares, Coleman Mark has 47.44 thousand shares and Pizzie Nick has 42.19 thousand shares. Over the past six months, insider transactions show net selling. They sold 692.22 thousand shares across 25 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Axsome Therapeutics generated $270.60M in revenue, or $5.96 per share. Gross margin was 87.84%, operating margin -67.59%, and net profit margin -88.41%. Returns are negative, with ROA at -40.67% and ROE at -125.27%.
On valuation metrics, Axsome Therapeutics trades at a P/E of -40.36, P/S of 16.63 and P/B of 125.65. The current ratio is 1.57 and quick ratio is 1.50. Operationally, the company’s inventory turnover is 1.92 and cash conversion cycle is -115.63 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 2.96, supported by a cash flow-to-debt ratio of -0.46.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Axsome Therapeutics posted revenue of $270.60M, down slightly from $50.04M in the prior quarter. Gross profit was $237.70M (margin 87.84%). Operating income was - $182.91M (margin -67.6%). Net income was- $239.24M (EPS - $5.27).
The company ended the quarter with $386.19M in cash and short-term investments, a total debt of $186.37M, and net debt of - $199.82M. Total assets were $588.24M, with equity of $190.98M. Financials further reflected weakness, with operating cash flow of - $145.08M, free cash flow of - $145.66M, and capital expenditures of - $582.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Axsome Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.89%, with price expected at $197.22 by February 03, 2026, within a range of $190.79 to $204.28 3-Month Outlook: Projected rise of 81.82%, reaching $335.46 by April 16, 2026, with a range of $332.21 to $341.12. 1-Year Outlook: Projected gain of 5.92%, with price at $195.42 by January 15, 2027, within a range of $190.62 to $199.78.

Key Takeaways

Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares are flat 1.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Axsome Therapeutics, Inc. trading at a premium to the broader market with a P/E of -40.36. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $142.80, suggesting -22.6% downside. Our AI forecast model points to short-term strength (6.89% over two weeks), a medium-term rise (81.82% over three months), and a longer-term gain (5.92% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Axsome Therapeutics, Inc. (AXSM) stock price?

Axsome Therapeutics, Inc. (NASDAQ: AXSM) stock price is $188.11 in the last trading session. During the trading session, AXSM stock reached the peak price of $188.29 while $183.69 was the lowest point it dropped to. The percentage change in AXSM stock occurred in the recent session was 1.96% while the dollar amount for the price change in AXSM stock was $3.61.

AXSM's industry and sector of operation?

The NASDAQ listed AXSM is part of Biotechnology industry that operates in the broader Healthcare sector. Axsome Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AXSM?

Mr. Nick Pizzie CPA, M.B.A.
Chief Financial Officer
Mr. Hunter Murdock Esq.
Gen. Counsel & Sec.
Mr. Kevin Laliberte Pharm.D.
Executive Vice President of Product Strategy
Ms. Lori Englebert M.B.A.
Executive Vice President of Commercial & Bus. Devel.
Mr. Mark L. Jacobson
Chief Operating Officer & Sec.
Dr. Amanda Jones Pharm.D.
Senior Vice President of Clinical Devel.
Dr. Herriot Tabuteau M.D.
Founder, Chairman, Chief Executive Officer & Pres
Joseph Debrah-Afful CPA, M.B.A.
Director of Fin.

How AXSM did perform over past 52-week?

AXSM's closing price is 112.09% higher than its 52-week low of $86.99 where as its distance from 52-week high of $188.37 is -0.8%.

How many employees does AXSM have?

Number of AXSM employees currently stands at 712.

Link for AXSM official website?

Official Website of AXSM is: https://www.axsome.com

How do I contact AXSM?

AXSM could be contacted at phone 212 332 3241 and can also be accessed through its website. AXSM operates from 22 Cortlandt Street, New York City, NY 10007, United States.

How many shares of AXSM are traded daily?

AXSM stock volume for the day was 956.61K shares. The average number of AXSM shares traded daily for last 3 months was 635.1K.

What is the market cap of AXSM currently?

The market value of AXSM currently stands at $9.48B with its latest stock price at $188.11 and 50.41M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	712
Beta	0.43
Sales or Revenue	$270.60M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

AXSM Company Profile and Key Details

Axsome Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics

Earnings & Analyst Outlook